Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2011

01.03.2011

The significant role of mast cells in cancer

verfasst von: Khashayarsha Khazaie, Nichole R. Blatner, Mohammad Wasim Khan, Fotini Gounari, Elias Gounaris, Kristen Dennis, Andreas Bonertz, Fu-Nien Tsai, Matthew J. Strouch, Eric Cheon, Joseph D. Phillips, Philipp Beckhove, David J. Bentrem

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Mast cells (MC) are a bone marrow-derived, long-lived, heterogeneous cellular population that function both as positive and negative regulators of immune responses. They are arguably the most productive chemical factory in the body and influence other cells through both soluble mediators and cell-to-cell interaction. MC are commonly seen in various tumors and have been attributed alternatively with tumor rejection or tumor promotion. Tumor-infiltrating MC are derived both from sentinel and recruited progenitor cells. MC can directly influence tumor cell proliferation and invasion but also help tumors indirectly by organizing its microenvironment and modulating immune responses to tumor cells. Best known for orchestrating inflammation and angiogenesis, the role of MC in shaping adaptive immune responses has become a focus of recent investigations. MC mobilize T cells and antigen-presenting dendritic cells. They function as intermediaries in regulatory T cells (Treg)-induced tolerance but can also modify or reverse Treg-suppressive properties. The central role of MC in the control of innate and adaptive immunity endows them with the ability to tune the nature of host responses to cancer and ultimately influence the outcome of disease and fate of the cancer patient.
Literatur
1.
Chen, C. C., Grimbaldeston, M. A., Tsai, M., Weissman, I. L., & Galli, S. J. (2005). Identification of mast cell progenitors in adult mice. Proceedings of the National Academy of Sciences of the United States of America, 102, 11408–11413.PubMedCrossRef
2.
Arinobu, Y., Iwasaki, H., & Akashi, K. (2009). Origin of basophils and mast cells. Allergology International, 58, 21–28.PubMedCrossRef
3.
Enerback, L. (1966). Mast cells in rat gastrointestinal mucosa. 2. Dye-binding and metachromatic properties. Acta Pathologica et Microbiologica Scandinavica, 66, 303–312.PubMed
4.
Enerbaeck, L. (1986). Mast cell heterogeneity: The evolution of the concept of a specific mucosal mast cell. In A. D. Befus, J. Bienenstock, & J. A. Denburg (Eds.) Mast cell differentiation and heterogeneity (pp. 1–26). Raven Press.
5.
Befus, A. D., Pearce, F. L., Gauldie, J., Horsewood, P., & Bienenstock, J. (1982). Mucosal mast cells. I. Isolation and functional characteristics of rat intestinal mast cells. Journal of Immunology, 128, 2475–2480.
6.
Metcalfe, D. D., Baram, D., & Mekori, Y. A. (1997). Mast cells. Physiological Reviews, 77, 1033–1079.PubMed
7.
Irani, A. A., Schechter, N. M., Craig, S. S., DeBlois, G., & Schwartz, L. B. (1986). Two types of human mast cells that have distinct neutral protease compositions. Proceedings of the National Academy of Sciences of the United States of America, 83, 4464–4468.PubMedCrossRef
8.
Arck, P. C., Handjiski, B., Hagen, E., Joachim, R., Klapp, B. F., & Paus, R. (2001). Indications for a ‘brain-hair follicle axis (BHA)’: Inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P. The FASEB Journal, 15, 2536–2538.PubMed
9.
Hallgren, J., & Gurish, M. F. (2007). Pathways of murine mast cell development and trafficking: Tracking the roots and routes of the mast cell. Immunological Reviews, 217, 8–18.PubMedCrossRef
10.
Gounaris, E., Erdman, S. E., Restaino, C., Gurish, M. F., Friend, D. S., Gounari, F., et al. (2007). Mast cells are an essential hematopoietic component for polyp development. Proceedings of the National Academy of Sciences of the United States of America, 104, 19977–19982.PubMedCrossRef
11.
Kumamoto, T., Shalhevet, D., Matsue, H., Mummert, M. E., Ward, B. R., Jester, J. V., et al. (2003). Hair follicles serve as local reservoirs of skin mast cell precursors. Blood, 102, 1654–1660.PubMedCrossRef
12.
Kasugai, T., Tei, H., Okada, M., Hirota, S., Morimoto, M., Yamada, M., et al. (1995). Infection with Nippostrongylus brasiliensis induces invasion of mast cell precursors from peripheral blood to small intestine. Blood, 85, 1334–1340.PubMed
13.
Rodewald, H. R., Dessing, M., Dvorak, A. M., & Galli, S. J. (1996). Identification of a committed precursor for the mast cell lineage. Science, 271, 818–822.PubMedCrossRef
14.
Nakano, T., Sonoda, T., Hayashi, C., Yamatodani, A., Kanayama, Y., Yamamura, T., et al. (1985). Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. The Journal of Experimental Medicine, 162, 1025–1043.PubMedCrossRef
15.
Gurish, M. F., Pear, W. S., Stevens, R. L., Scott, M. L., Sokol, K., Ghildyal, N., et al. (1995). Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity, 3, 175–186.PubMedCrossRef
16.
Lu, L. F., Lind, E. F., Gondek, D. C., Bennett, K. A., Gleeson, M. W., Pino-Lagos, K., et al. (2006). Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature, 442, 997–1002.PubMedCrossRef
17.
Maltby, S., Khazaie, K., & McNagny, K. M. (2009). Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochimica et Biophysica Acta, 1796, 19–26.PubMed
18.
Galli, S. J. (1990). New insights into “the riddle of the mast cells”: Microenvironmental regulation of mast cell development and phenotypic heterogeneity. Laboratory Investigation, 62, 5–33.PubMed
19.
Gurish, M. F., & Austen, K. F. (2001). The diverse roles of mast cells. The Journal of Experimental Medicine, 194, F1–F5.PubMedCrossRef
20.
Grimbaldeston, M. A., Metz, M., Yu, M., Tsai, M., & Galli, S. J. (2006). Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Current Opinion in Immunology, 18, 751–760.PubMedCrossRef
21.
Kanakura, Y., Thompson, H., Nakano, T., Yamamura, T., Asai, H., Kitamura, Y., et al. (1988). Multiple bidirectional alterations of phenotype and changes in proliferative potential during the in vitro and in vivo passage of clonal mast cell populations derived from mouse peritoneal mast cells. Blood, 72, 877–885.PubMed
22.
Sonoda, S., Sonoda, T., Nakano, T., Kanayama, Y., Kanakura, Y., Asai, H., et al. (1986). Development of mucosal mast cells after injection of a single connective tissue-type mast cell in the stomach mucosa of genetically mast cell-deficient W/Wv mice. Journal of Immunology, 137, 1319–1322.
23.
Boyce, J. A., Mellor, E. A., Perkins, B., Lim, Y. C., & Luscinskas, F. W. (2002). Human mast cell progenitors use alpha4-integrin, VCAM-1, and PSGL-1 E-selectin for adhesive interactions with human vascular endothelium under flow conditions. Blood, 99, 2890–2896.PubMedCrossRef
24.
Gurish, M. F., Tao, H., Abonia, J. P., Arya, A., Friend, D. S., Parker, C. M., et al. (2001). Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing. The Journal of Experimental Medicine, 194, 1243–1252.PubMedCrossRef
25.
Abonia, J. P., Austen, K. F., Rollins, B. J., Joshi, S. K., Flavell, R. A., Kuziel, W. A., et al. (2005). Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood, 105, 4308–4313.PubMedCrossRef
26.
Abonia, J. P., Hallgren, J., Jones, T., Shi, T., Xu, Y., Koni, P., et al. (2006). Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood, 108, 1588–1594.PubMedCrossRef
27.
Hallgren, J., Jones, T. G., Abonia, J. P., Xing, W., Humbles, A., Austen, K. F., et al. (2007). Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors. Proceedings of the National Academy of Sciences of the United States of America, 104, 20478–20483.PubMedCrossRef
28.
Galli, S. J., Tsai, M., & Wershil, B. K. (1993). The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. The American Journal of Pathology, 142, 965–974.PubMed
29.
Moller, C., Alfredsson, J., Engstrom, M., Wootz, H., Xiang, Z., Lennartsson, J., et al. (2005). Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood, 106, 1330–1336.PubMedCrossRef
30.
Meininger, C. J., Yano, H., Rottapel, R., Bernstein, A., Zsebo, K. M., & Zetter, B. R. (1992). The c-kit receptor ligand functions as a mast cell chemoattractant. Blood, 79, 958–963.PubMed
31.
Gilfillan, A. M., & Rivera, J. (2009). The tyrosine kinase network regulating mast cell activation. Immunological Reviews, 228, 149–169.PubMedCrossRef
32.
Okayama, Y., & Kawakami, T. (2006). Development, migration, and survival of mast cells. Immunologic Research, 34, 97–115.PubMedCrossRef
33.
Taylor, A. M., Galli, S. J., & Coleman, J. W. (1995). Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: Dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology, 86, 427–433.PubMed
34.
Galli, S. J., Tsai, M., Gordon, J. R., Geissler, E. N., & Wershil, B. K. (1992). Analyzing mast cell development and function using mice carrying mutations at W/c-kit or Sl/MGF (SCF) loci. Annals of the New York Academy of Sciences, 664, 69–88.PubMedCrossRef
35.
Nocka, K., Tan, J. C., Chiu, E., Chu, T. Y., Ray, P., Traktman, P., et al. (1990). Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. The EMBO Journal, 9, 1805–1813.PubMed
36.
Pittoni, P., Piconese, S., Tripodo, C., & Colombo, M. P. (2010). Tumor-intrinsic and -extrinsic roles of c-Kit: Mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene.
37.
Bellone, G., Smirne, C., Carbone, A., Buffolino, A., Scirelli, T., Prati, A., et al. (2006). KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. International Journal of Oncology, 29, 851–859.PubMed
38.
Huang, B., Lei, Z., Zhang, G. M., Li, D., Song, C., Li, B., et al. (2008). SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood, 112, 1269–1279.PubMedCrossRef
39.
Lu-Kuo, J. M., Fruman, D. A., Joyal, D. M., Cantley, L. C., & Katz, H. R. (2000). Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. The Journal of Biological Chemistry, 275, 6022–6029.PubMedCrossRef
40.
Samayawardhena, L. A., & Pallen, C. J. (2008). Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. The Journal of Biological Chemistry, 283, 29175–29185.PubMedCrossRef
41.
Gounaris, E., Blatner, N. R., Dennis, K., Magnusson, F., Gurish, M. F., Strom, T. B., et al. (2009). T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Research, 69, 5490–5497.PubMedCrossRef
42.
Jones, T. G., Hallgren, J., Humbles, A., Burwell, T., Finkelman, F. D., Alcaide, P., et al. (2009). Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells. Journal of Immunology, 183, 5251–5260.CrossRef
43.
Chen, M. L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., et al. (2005). Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proceedings of the National Academy of Sciences of the United States of America, 102, 419–424.PubMedCrossRef
44.
Mempel, T. R., Pittet, M. J., Khazaie, K., Weninger, W., Weissleder, R., von Boehmer, H., et al. (2006). Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity, 25, 129–141.PubMedCrossRef
45.
Nummer, D., Suri-Payer, E., Schmitz-Winnenthal, H., Bonertz, A., Galindo, L., Antolovich, D., et al. (2007). Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. Journal of the National Cancer Institute, 99, 1188–1199.PubMedCrossRef
46.
Wagner, P., Koch, M., Nummer, D., Palm, S., Galindo, L., Autenrieth, D., et al. (2008). Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Annals of Surgical Oncology, 15, 2310–2317.PubMedCrossRef
47.
Bonertz, A., Weitz, J., Pietsch, D. H., Rahbari, N. N., Schlude, C., Ge, Y., et al. (2009). Antigen-specific Treg control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. Journal of Clinical Investigation, 119, 3311–3321.PubMed
48.
Blatner, N. R., Bonertz, A., Beckhove, P., Cheon, E. C., Krantz, S. B., Strouch, M., et al. (2010). In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 107, 6430–6435.PubMedCrossRef
49.
Ruitenberg, E. J., & Elgersma, A. (1976). Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature, 264, 258–260.PubMedCrossRef
50.
Schmitt, E., Huls, C., Nagel, B., & Rude, E. (1990). Characterization of a T-cell-derived mast cell costimulatory activity (MCA) that acts synergistically with interleukin 3 and interleukin 4 on the growth of murine mast cells. Cytokine, 2, 407–415.PubMedCrossRef
51.
Alcaide, P., Jones, T. G., Lord, G. M., Glimcher, L. H., Hallgren, J., Arinobu, Y., et al. (2007). Dendritic cell expression of the transcription factor T-bet regulates mast cell progenitor homing to mucosal tissue. The Journal of Experimental Medicine, 204, 431–439.PubMedCrossRef
52.
Irani, A. M., Craig, S. S., DeBlois, G., Elson, C. O., Schechter, N. M., & Schwartz, L. B. (1987). Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. Journal of Immunology, 138, 4381–4386.
53.
Jones, T. G., Finkelman, F. D., Austen, K. F., & Gurish, M. F. (2010). T regulatory cells control antigen-induced recruitment of mast cell progenitors to the lungs of C57BL/6 mice. Journal of Immunology, 185, 1804–1811.CrossRef
54.
Shin, K., Gurish, M. F., Friend, D. S., Pemberton, A. D., Thornton, E. M., Miller, H. R., et al. (2006). Lymphocyte-independent connective tissue mast cells populate murine synovium. Arthritis and Rheumatism, 54, 2863–2871.PubMedCrossRef
55.
Boesiger, J., Tsai, M., Maurer, M., Yamaguchi, M., Brown, L. F., Claffey, K. P., et al. (1998). Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. The Journal of Experimental Medicine, 188, 1135–1145.PubMedCrossRef
56.
Blair, R. J., Meng, H., Marchese, M. J., Ren, S., Schwartz, L. B., Tonnesen, M. G., et al. (1997). Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. Journal of Clinical Investigation, 99, 2691–2700.PubMedCrossRef
57.
Gordon, J. R., & Galli, S. J. (1990). Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature, 346, 274–276.PubMedCrossRef
58.
Mannel, D. N., Hultner, L., & Echtenacher, B. (1996). Critical protective role of mast cell-derived tumour necrosis factor in bacterial infection. Research in Immunology, 147, 491–493.PubMedCrossRef
59.
Echtenacher, B., Mannel, D. N., & Hultner, L. (1996). Critical protective role of mast cells in a model of acute septic peritonitis. Nature, 381, 75–77.PubMedCrossRef
60.
Malaviya, R., Ikeda, T., Ross, E., & Abraham, S. N. (1996). Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature, 381, 77–80.PubMedCrossRef
61.
Maurer, M., Echtenacher, B., Hultner, L., Kollias, G., Mannel, D. N., Langley, K. E., et al. (1998). The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. The Journal of Experimental Medicine, 188, 2343–2348.PubMedCrossRef
62.
Feger, F., Varadaradjalou, S., Gao, Z., Abraham, S. N., & Arock, M. (2002). The role of mast cells in host defense and their subversion by bacterial pathogens. Trends in Immunology, 23, 151–158.PubMedCrossRef
63.
Bochner, B. S., Charlesworth, E. N., Lichtenstein, L. M., Derse, C. P., Gillis, S., Dinarello, C. A., et al. (1990). Interleukin-1 is released at sites of human cutaneous allergic reactions. The Journal of Allergy and Clinical Immunology, 86, 830–839.PubMedCrossRef
64.
Nigrovic, P. A., Binstadt, B. A., Monach, P. A., Johnsen, A., Gurish, M., Iwakura, Y., et al. (2007). Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proceedings of the National Academy of Sciences of the United States of America, 104, 2325–2330.PubMedCrossRef
65.
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436–444.PubMedCrossRef
66.
Cook, G. P., Savic, S., Wittmann, M., & McDermott, M. F. (2010). The NLRP3 inflammasome, a target for therapy in diverse disease states. European Journal of Immunology, 40, 631–634.PubMedCrossRef
67.
Kim, G. Y., Lee, J. W., Ryu, H. C., Wei, J. D., Seong, C. M., & Kim, J. H. (2010). Proinflammatory cytokine IL-1beta stimulates IL-8 synthesis in mast cells via a leukotriene B4 receptor 2-linked pathway, contributing to angiogenesis. Journal of Immunology, 184, 3946–3954.CrossRef
68.
Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 320, 674–677.PubMedCrossRef
69.
Depinay, N., Hacini, F., Beghdadi, W., Peronet, R., & Mecheri, S. (2006). Mast cell-dependent down-regulation of antigen-specific immune responses by mosquito bites. Journal of Immunology, 176, 4141–4146.
70.
Kennedy Norton, S., Barnstein, B., Brenzovich, J., Bailey, D. P., Kashyap, M., Speiran, K., et al. (2008). IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. Journal of Immunology, 180, 2848–2854.
71.
Huang, C., Sali, A., & Stevens, R. L. (1998). Regulation and function of mast cell proteases in inflammation. Journal of Clinical Immunology, 18, 169–183.PubMedCrossRef
72.
Ghildyal, N., Friend, D. S., Freelund, R., Austen, K. F., McNeil, H. P., Schiller, V., et al. (1994). Lack of expression of the tryptase mouse mast cell protease 7 in mast cells of the C57BL/6J mouse. Journal of Immunology, 153, 2624–2630.
73.
Stevens, R. L., Friend, D. S., McNeil, H. P., Schiller, V., Ghildyal, N., & Austen, K. F. (1994). Strain-specific and tissue-specific expression of mouse mast cell secretory granule proteases. Proceedings of the National Academy of Sciences of the United States of America, 91, 128–132.PubMedCrossRef
74.
Miller, H. R., & Pemberton, A. D. (2002). Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology, 105, 375–390.PubMedCrossRef
75.
Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M., Williams, C. M., & Tsai, M. (2005). Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. Annual Review of Immunology, 23, 749–786.PubMedCrossRef
76.
Weller, C. L., Collington, S. J., Brown, J. K., Miller, H. R., Al-Kashi, A., Clark, P., et al. (2005). Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. The Journal of Experimental Medicine, 201, 1961–1971.PubMedCrossRef
77.
Cheon, E. C., Khazaie, K., Khan, M. W., Strouch, M. J., Krantz, S. B., Phillips, J., et al. (2010). Mast cell 5-Lipoxygenase activity promotes intestinal polyposis in APCΔ468 mice. Cancer Research, (in press).
78.
Jain, S., Harris, J., & Ware, J. (2010). Platelets: Linking hemostasis and cancer. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 2362–2367.PubMedCrossRef
79.
Blank, U., & Rivera, J. (2004). The ins and outs of IgE-dependent mast-cell exocytosis. Trends in Immunology, 25, 266–273.PubMedCrossRef
80.
Kim, M. S., Radinger, M., & Gilfillan, A. M. (2008). The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends in Immunology, 29, 493–501.PubMedCrossRef
81.
Ching, T. T., Hsu, A. L., Johnson, A. J., & Chen, C. S. (2001). Phosphoinositide 3-kinase facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3, 4, 5-trisphosphate-sensitive Ca(2+) entry mechanism. The Journal of Biological Chemistry, 276, 14814–14820.PubMedCrossRef
82.
Nigrovic, P. A., Malbec, O., Lu, B., Markiewski, M. M., Kepley, C., Gerard, N., et al. (2010). C5a receptor enables participation of mast cells in immune complex arthritis independently of Fcgamma receptor modulation. Arthritis and Rheumatism, 62, 3322–3333.PubMedCrossRef
83.
Gommerman, J. L., Oh, D. Y., Zhou, X., Tedder, T. F., Maurer, M., Galli, S. J., et al. (2000). A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: A potential mechanism for mast cell activation. Journal of Immunology, 165, 6915–6921.
84.
Johnson, A. R., Hugli, T. E., & Muller-Eberhard, H. J. (1975). Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology, 28, 1067–1080.PubMed
85.
Marshall, J. S. (2004). Mast-cell responses to pathogens. Nature Reviews Immunology, 4, 787–799.PubMedCrossRef
86.
Prodeus, A. P., Zhou, X., Maurer, M., Galli, S. J., & Carroll, M. C. (1997). Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature, 390, 172–175.PubMedCrossRef
87.
Wojtecka-Lukasik, E., & Maslinski, S. (1992). Fibronectin and fibrinogen degradation products stimulate PMN-leukocyte and mast cell degranulation. Journal of Physiology and Pharmacology, 43, 173–181.PubMed
88.
Shefler, I., Salamon, P., Reshef, T., Mor, A., & Mekori, Y. A. (2010). T cell-induced mast cell activation: A role for microparticles released from activated T cells. Journal of Immunology, 185, 4206–4212.CrossRef
89.
Dvorak, A. M. (2005). Ultrastructural studies of human basophils and mast cells. The Journal of Histochemistry and Cytochemistry, 53, 1043–1070.PubMedCrossRef
90.
Crivellato, E., Nico, B., Gallo, V. P., & Ribatti, D. (2010). Cell secretion mediated by granule-associated vesicle transport: A glimpse at evolution. Anatomical Record (Hoboken), 293, 1115–1124.CrossRef
91.
Dvorak, A. M. (1991). Basophil and mast cell degranulation and recovery. In Blood cell biochemistry. Plenum Press, vol 4.
92.
Toth-Jakatics, R., Jimi, S., Takebayashi, S., & Kawamoto, N. (2000). Cutaneous malignant melanoma: Correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Human Pathology, 31, 955–960.PubMedCrossRef
93.
Ribatti, D., Vacca, A., Ria, R., Marzullo, A., Nico, B., Filotico, R., et al. (2003). Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. European Journal of Cancer, 39, 666–674.PubMedCrossRef
94.
Ribatti, D., Vacca, A., Marzullo, A., Nico, B., Ria, R., Roncali, L., et al. (2000). Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. International Journal of Cancer, 85, 171–175.
95.
Imada, A., Shijubo, N., Kojima, H., & Abe, S. (2000). Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. The European Respiratory Journal, 15, 1087–1093.PubMedCrossRef
96.
Terada, T., & Matsunaga, Y. (2000). Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Hepatology, 33, 961–966.PubMedCrossRef
97.
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development, 13, 1382–1397.CrossRef
98.
Takanami, I., Takeuchi, K., & Naruke, M. (2000). Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer, 88, 2686–2692.PubMedCrossRef
99.
Nonomura, N., Takayama, H., Nishimura, K., Oka, D., Nakai, Y., Shiba, M., et al. (2007). Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. British Journal of Cancer, 97, 952–956.PubMed
100.
Johansson, A., Rudolfsson, S., Hammarsten, P., Halin, S., Pietras, K., Jones, J., et al. (2010). Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. The American Journal of Pathology, 177, 1031–1041.PubMedCrossRef
101.
Tan, P. H., Jayabaskar, T., Yip, G., Tan, Y., Hilmy, M., Selvarajan, S., et al. (2005). p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: A tissue microarray study. Modern Pathology, 18, 1527–1534.PubMedCrossRef
102.
Djordjevic, B., & Hanna, W. M. (2008). Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon. Modern Pathology, 21, 1238–1245.PubMedCrossRef
103.
Taskinen, M., Karjalainen-Lindsberg, M. L., & Leppa, S. (2008). Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood, 111, 4664–4667.PubMedCrossRef
104.
Beer, T. W., Ng, L. B., & Murray, K. (2008). Mast cells have prognostic value in Merkel cell carcinoma. The American Journal of Dermatopathology, 30, 27–30.PubMedCrossRef
105.
Molin, D., Edstrom, A., Glimelius, I., Glimelius, B., Nilsson, G., Sundstrom, C., et al. (2002). Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma. British Journal Haematology, 119, 122–124.CrossRef
106.
Glimelius, I., Edstrom, A., Fischer, M., Nilsson, G., Sundstrom, C., Molin, D., et al. (2005). Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia, 19, 2360–2362.PubMedCrossRef
107.
Yang, F. C., Chen, S., Clegg, T., Li, X., Morgan, T., Estwick, S. A., et al. (2006). Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Human Molecular Genetics, 15, 2421–2437.PubMedCrossRef
108.
Crivellato, E., Nico, B., & Ribatti, D. (2008). Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Letters, 269, 1–6.PubMedCrossRef
109.
Gulubova, M., & Vlaykova, T. (2009). Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. Journal of Gastroenterology and Hepatology, 24, 1265–1275.PubMedCrossRef
110.
Yodavudh, S., Tangjitgamol, S., & Puangsa-art, S. (2008). Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. Journal of the Medical Association of Thailand, 91, 723–732.PubMed
111.
Acikalin, M. F., Oner, U., Topcu, I., Yasar, B., Kiper, H., & Colak, E. (2005). Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Digestive and Liver Disease, 37, 162–169.PubMedCrossRef
112.
Strouch, M. J., Cheon, E. C., Salabat, M. R., Krantz, S. B., Gounaris, E., Melstrom, L. G., et al. (2010). Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clinical Cancer Research, 16, 2257–2265.PubMedCrossRef
113.
Carlini, M. J., Dalurzo, M. C., Lastiri, J. M., Smith, D. E., Vasallo, B. C., Puricelli, L. I., et al. (2010). Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Human Pathology, 41, 697–705.PubMedCrossRef
114.
Ibaraki, T., Muramatsu, M., Takai, S., Jin, D., Maruyama, H., Orino, T., et al. (2005). The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. European Journal of Cardiothoracic Surgery, 28, 617–621.PubMedCrossRef
115.
Ju, M. J., Qiu, S. J., Gao, Q., Fan, J., Cai, M. Y., Li, Y. W., et al. (2009). Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Science, 100, 1267–1274.PubMedCrossRef
116.
Ju, M. J., Qiu, S. J., Fan, J., Xiao, Y. S., Gao, Q., Zhou, J., et al. (2009). Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. American Journal of Clinical Pathology, 131, 498–510.PubMedCrossRef
117.
Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003). Immune enhancement of skin carcinogenesis by CD4+ T cells. The Journal of Experimental Medicine, 197, 1017–1028.PubMedCrossRef
118.
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 7, 411–423.PubMedCrossRef
119.
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell, 17, 121–134.PubMedCrossRef
120.
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., et al. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16, 91–102.PubMedCrossRef
121.
Samoszuk, M., & Corwin, M. A. (2003). Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. International Journal of Cancer, 107, 159–163.CrossRef
122.
Soucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B., & Evan, G. I. (2007). Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Natural Medicines, 13, 1211–1218.CrossRef
123.
Samoszuk, M. K., Su, M. Y., Najafi, A., & Nalcioglu, O. (2001). Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. The American Journal of Pathology, 159, 245–251.PubMedCrossRef
124.
Melillo, R. M., Guarino, V., Avilla, E., Galdiero, M. R., Liotti, F., Prevete, N., et al. (2010). Mast cells have a protumorigenic role in human thyroid cancer. Oncogene, 29, 6203–6215.PubMedCrossRef
125.
Sinnamon, M. J., Carter, K. J., Sims, L. P., Lafleur, B., Fingleton, B., & Matrisian, L. M. (2008). A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis, 29, 880–886.PubMedCrossRef
126.
Ribatti, D., & Crivellato, E. (2009). The controversial role of mast cells in tumor growth. International Review of Cell and Molecular Biology, 275, 89–131.PubMedCrossRef
127.
Nigrovic, P. A., Gray, D. H., Jones, T., Hallgren, J., Kuo, F. C., Chaletzky, B., et al. (2008). Genetic inversion in mast cell-deficient (W(sh)) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. The American Journal of Pathology, 173, 1693–1701.PubMedCrossRef
128.
Pulimood, A. B., Mathan, M. M., & Mathan, V. I. (1998). Quantitative and ultrastructural analysis of rectal mucosal mast cells in acute infectious diarrhea. Digestive Diseases and Sciences, 43, 2111–2116.PubMedCrossRef
129.
Carothers, A. M., Moran, A. E., Cho, N. L., Redston, M., & Bertagnolli, M. M. (2006). Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Research, 66, 6432–6438.PubMedCrossRef
130.
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., et al. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. The New England Journal of Medicine, 355, 873–884.PubMedCrossRef
131.
Masini, E., Bechi, P., Dei, R., Di Bello, M. G., & Sacchi, T. B. (1994). Helicobacter pylori potentiates histamine release from rat serosal mast cells induced by bile acids. Digestive Diseases and Sciences, 39, 1493–1500.PubMedCrossRef
132.
Nakajima, S., Krishnan, B., Ota, H., Segura, A. M., Hattori, T., Graham, D. Y., et al. (1997). Mast cell involvement in gastritis with or without Helicobacter pylori infection. Gastroenterology, 113, 746–754.PubMedCrossRef
133.
Plebani, M., Basso, D., Vianello, F., & Di Mario, F. (1994). Helicobacter pylori activates gastric mucosal mast cells. Digestive Diseases and Sciences, 39, 1592–1593.PubMedCrossRef
134.
Rogers, A. B., & Fox, J. G. (2004). Inflammation and cancer: I. Rodent models of infectious gastrointestinal liver cancer. American Journal of Physiology. Gastrointestinal and Liver Physiology, 286, G361–G366.PubMedCrossRef
135.
Rao, V. P., Poutahidis, T., Ge, Z., Nambiar, P. R., Boussahmain, C., Wang, Y. Y., et al. (2006). Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Research, 66, 7395–7400.PubMedCrossRef
136.
Nielsen, H. J., Hansen, U., Christensen, I. J., Reimert, C. M., Brunner, N., & Moesgaard, F. (1999). Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. The Journal of Pathology, 189, 487–495.PubMedCrossRef
137.
Ogino, S., Shima, K., Baba, Y., Nosho, K., Irahara, N., Kure, S., et al. (2009). Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology, 136, 1242–1250.PubMedCrossRef
138.
Welsh, T. J., Green, R. H., Richardson, D., Waller, D. A., O’Byrne, K. J., & Bradding, P. (2005). Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. Journal of Clinical Oncology, 23, 8959–8967.PubMedCrossRef
139.
Ali, G., Boldrini, L., Lucchi, M., Picchi, A., Dell’Omodarme, M., Prati, M. C., et al. (2009). Treatment with interleukin-2 in malignant pleural mesothelioma: Immunological and angiogenetic assessment and prognostic impact. British Journal of Cancer, 101, 1869–1875.PubMedCrossRef
140.
Ali, G., Boldrini, L., Lucchi, M., Mussi, A., Corsi, V., & Fontanini, G. (2009). Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor. Journal of Thoracic Oncology, 4, 348–354.PubMedCrossRef
141.
Hedstrom, G., Berglund, M., Molin, D., Fischer, M., Nilsson, G., Thunberg, U., et al. (2007). Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. British Journal Haematology, 138, 68–71.CrossRef
142.
Fleischmann, A., Schlomm, T., Kollermann, J., Sekulic, N., Huland, H., Mirlacher, M., et al. (2009). Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. The Prostate, 69, 976–981.PubMedCrossRef
143.
Kankkunen, J. P., Harvima, I. T., & Naukkarinen, A. (1997). Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. International Journal of Cancer, 72, 385–388.CrossRef
144.
Dabiri, S., Huntsman, D., Makretsov, N., Cheang, M., Gilks, B., Bajdik, C., et al. (2004). The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Modern Pathology, 17, 690–695.PubMedCrossRef
145.
Rajput, A. B., Turbin, D. A., Cheang, M. C., Voduc, D. K., Leung, S., Gelmon, K. A., et al. (2008). Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4, 444 cases. Breast Cancer Research and Treatment, 107, 249–257.PubMedCrossRef
146.
Schechter, N. M., Brass, L. F., Lavker, R. M., & Jensen, P. J. (1998). Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts. Journal of Cellular Physiology, 176, 365–373.PubMedCrossRef
147.
Corvera, C. U., Dery, O., McConalogue, K., Bohm, S. K., Khitin, L. M., Caughey, G. H., et al. (1997). Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. Journal of Clinical Investigation, 100, 1383–1393.PubMedCrossRef
148.
Kawabata, A. (2003). Gastrointestinal functions of proteinase-activated receptors. Life Sciences, 74, 247–254.PubMedCrossRef
149.
Winter, M. C., Shasby, S. S., Ries, D. R., & Shasby, D. M. (2006). PAR2 activation interrupts E-cadherin adhesion and compromises the airway epithelial barrier: Protective effect of beta-agonists. American Journal of Physiology. Lung Cellular and Molecular Physiology, 291, L628–L635.PubMedCrossRef
150.
Yoshii, M., Jikuhara, A., Mori, S., Iwagaki, H., Takahashi, H. K., Nishibori, M., et al. (2005). Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. Journal of Pharmacological Sciences, 98, 450–458.PubMedCrossRef
151.
MacNaughton, W. K. (2005). Epithelial effects of proteinase-activated receptors in the gastrointestinal tract. Memórias do Instituto Oswaldo Cruz, 100(Suppl 1), 211–215.PubMed
152.
Morris, D. R., Ding, Y., Ricks, T. K., Gullapalli, A., Wolfe, B. L., & Trejo, J. (2006). Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Research, 66, 307–314.PubMedCrossRef
153.
Cairns, J. A., & Walls, A. F. (1996). Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. Journal of Immunology, 156, 275–283.
154.
Berger, P., Perng, D. W., Thabrew, H., Compton, S. J., Cairns, J. A., McEuen, A. R., et al. (2001). Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. Journal of Applied Physiology, 91, 1372–1379.PubMed
155.
Gruber, B. L., Kew, R. R., Jelaska, A., Marchese, M. J., Garlick, J., Ren, S., et al. (1997). Human mast cells activate fibroblasts: Tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. Journal of Immunology, 158, 2310–2317.
156.
Levi-Schaffer, F., & Piliponsky, A. M. (2003). Tryptase, a novel link between allergic inflammation and fibrosis. Trends in Immunology, 24, 158–161.PubMedCrossRef
157.
Frungieri, M. B., Weidinger, S., Meineke, V., Kohn, F. M., & Mayerhofer, A. (2002). Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: Possible relevance to human fibrotic disorders. Proceedings of the National Academy of Sciences of the United States of America, 99, 15072–15077.PubMedCrossRef
158.
Mizutani, H., Schechter, N., Lazarus, G., Black, R. A., & Kupper, T. S. (1991). Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. The Journal of Experimental Medicine, 174, 821–825.PubMedCrossRef
159.
Groschwitz, K. R., Ahrens, R., Osterfeld, H., Gurish, M. F., Han, X., Abrink, M., et al. (2009). Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 106, 22381–22386.PubMedCrossRef
160.
Forbes, E. E., Groschwitz, K., Abonia, J. P., Brandt, E. B., Cohen, E., Blanchard, C., et al. (2008). IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. The Journal of Experimental Medicine, 205, 897–913.PubMedCrossRef
161.
Flint, N., Cove, F. L., & Evans, G. S. (1994). Heparin stimulates the proliferation of intestinal epithelial cells in primary culture. Journal of Cell Science, 107(Pt 2), 401–411.PubMed
162.
Szlosarek, P., Charles, K. A., & Balkwill, F. R. (2006). Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer, 42, 745–750.PubMedCrossRef
163.
Stevens, R. L., & Adachi, R. (2007). Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunological Reviews, 217, 155–167.PubMedCrossRef
164.
McNeil, H. P., Adachi, R., & Stevens, R. L. (2007). Mast cell-restricted tryptases: Structure and function in inflammation and pathogen defense. The Journal of Biological Chemistry, 282, 20785–20789.PubMedCrossRef
165.
Trivedi, N. N., & Caughey, G. H. (2010). Mast cell peptidases: Chameleons of innate immunity and host defense. American Journal of Respiratory Cell and Molecular Biology, 42, 257–267.PubMedCrossRef
166.
Dabbous, M. K., Walker, R., Haney, L., Carter, L. M., Nicolson, G. L., & Woolley, D. E. (1986). Mast cells and matrix degradation at sites of tumour invasion in rat mammary adenocarcinoma. British Journal of Cancer, 54, 459–465.PubMedCrossRef
167.
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., et al. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 93, 411–422.PubMedCrossRef
168.
Fang, K. C., Wolters, P. J., Steinhoff, M., Bidgol, A., Blount, J. L., & Caughey, G. H. (1999). Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. Journal of Immunology, 162, 5528–5535.
169.
Tanaka, A., Arai, K., Kitamura, Y., & Matsuda, H. (1999). Matrix metalloproteinase-9 production, a newly identified function of mast cell progenitors, is downregulated by c-kit receptor activation. Blood, 94, 2390–2395.PubMed
170.
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481–490.PubMedCrossRef
171.
McKerrow, J. H., Bhargava, V., Hansell, E., Huling, S., Kuwahara, T., Matley, M., et al. (2000). A functional proteomics screen of proteases in colorectal carcinoma. Molecular Medicine, 6, 450–460.PubMed
172.
Palermo, C., & Joyce, J. A. (2008). Cysteine cathepsin proteases as pharmacological targets in cancer. Trends in Pharmacological Sciences, 29, 22–28.PubMedCrossRef
173.
Xiang, M., Gu, Y., Zhao, F., Lu, H., Chen, S., & Yin, L. (2010). Mast cell tryptase promotes breast cancer migration and invasion. Oncology Reports, 23, 615–619.PubMed
174.
Cairns, J. A., & Walls, A. F. (1997). Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. Journal of Clinical Investigation, 99, 1313–1321.PubMedCrossRef
175.
Hebda, P. A., Collins, M. A., & Tharp, M. D. (1993). Mast cell and myofibroblast in wound healing. Dermatologic Clinics, 11, 685–696.PubMed
176.
Gailit, J., Marchese, M. J., Kew, R. R., & Gruber, B. L. (2001). The differentiation and function of myofibroblasts is regulated by mast cell mediators. Journal of Investigative Dermatology, 117, 1113–1119.PubMedCrossRef
177.
Mekori, Y. A., & Metcalfe, D. D. (1999). Mast cell-T cell interactions. The Journal of Allergy and Clinical Immunology, 104, 517–523.PubMedCrossRef
178.
Baram, D., Vaday, G. G., Salamon, P., Drucker, I., Hershkoviz, R., & Mekori, Y. A. (2001). Human mast cells release metalloproteinase-9 on contact with activated T cells: Juxtacrine regulation by TNF-alpha. Journal of Immunology, 167, 4008–4016.
179.
Brill, A., Baram, D., Sela, U., Salamon, P., Mekori, Y. A., & Hershkoviz, R. (2004). Induction of mast cell interactions with blood vessel wall components by direct contact with intact T cells or T cell membranes in vitro. Clinical and Experimental Allergy, 34, 1725–1731.PubMedCrossRef
180.
Theoharides, T. C., Kempuraj, D., Kourelis, T., & Manola, A. (2008). Human mast cells stimulate activated T cells: Implications for multiple sclerosis. Annals of the New York Academy of Sciences, 1144, 74–82.PubMedCrossRef
181.
Nakae, S., Ho, L. H., Yu, M., Monteforte, R., Iikura, M., Suto, H., et al. (2007). Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. The Journal of Allergy and Clinical Immunology, 120, 48–55.PubMedCrossRef
182.
Suto, H., Nakae, S., Kakurai, M., Sedgwick, J. D., Tsai, M., & Galli, S. J. (2006). Mast cell-associated TNF promotes dendritic cell migration. Journal of Immunology, 176, 4102–4112.
183.
Ren, S. R., Xu, L. B., Wu, Z. Y., Du, J., Gao, M. H., & Qu, C. F. (2010). Exogenous dendritic cell homing to draining lymph nodes can be boosted by mast cell degranulation. Cellular Immunology, 263, 204–211.PubMedCrossRef
184.
Demeure, C. E., Brahimi, K., Hacini, F., Marchand, F., Peronet, R., Huerre, M., et al. (2005). Anopheles mosquito bites activate cutaneous mast cells leading to a local inflammatory response and lymph node hyperplasia. Journal of Immunology, 174, 3932–3940.
185.
Jawdat, D. M., Rowden, G., & Marshall, J. S. (2006). Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. Journal of Immunology, 177, 1755–1762.
186.
Maurer, M., Lopez Kostka, S., Siebenhaar, F., Moelle, K., Metz, M., Knop, J., et al. (2006). Skin mast cells control T cell-dependent host defense in Leishmania major infections. The FASEB Journal, 20, 2460–2467.PubMedCrossRef
187.
McLachlan, J. B., Hart, J. P., Pizzo, S. V., Shelburne, C. P., Staats, H. F., Gunn, M. D., et al. (2003). Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nature Immunology, 4, 1199–1205.PubMedCrossRef
188.
Kashyap, M., Thornton, A. M., Norton, S. K., Barnstein, B., Macey, M., Brenzovich, J., et al. (2008). Cutting edge: CD4 T cell-mast cell interactions alter IgE receptor expression and signaling. Journal of Immunology, 180, 2039–2043.
189.
Shelburne, C. P., Nakano, H., St John, A. L., Chan, C., McLachlan, J. B., Gunn, M. D., et al. (2009). Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host & Microbe, 6, 331–342.CrossRef
190.
Kambayashi, T., Baranski, J. D., Baker, R. G., Zou, T., Allenspach, E. J., Shoag, J. E., et al. (2008). Indirect involvement of allergen-captured mast cells in antigen presentation. Blood, 111, 1489–1496.PubMedCrossRef
191.
Nakae, S., Suto, H., Iikura, M., Kakurai, M., Sedgwick, J. D., Tsai, M., et al. (2006). Mast cells enhance T cell activation: Importance of mast cell costimulatory molecules and secreted TNF. Journal of Immunology, 176, 2238–2248.
192.
Christy, A. L., & Brown, M. A. (2007). The multitasking mast cell: Positive and negative roles in the progression of autoimmunity. Journal of Immunology, 179, 2673–2679.
193.
Gregory, G. D., Raju, S. S., Winandy, S., & Brown, M. A. (2006). Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE. Journal of Clinical Investigation, 116, 1327–1336.PubMedCrossRef
194.
Kambayashi, T., Allenspach, E. J., Chang, J. T., Zou, T., Shoag, J. E., Reiner, S. L., et al. (2009). Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. Journal of Immunology, 182, 4686–4695.CrossRef
195.
Gri, G., Piconese, S., Frossi, B., Manfroi, V., Merluzzi, S., Tripodo, C., et al. (2008). CD4(+)CD25(+) regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity, 29, 771–781.PubMedCrossRef
196.
Yan, J., Wang, C., Du, R., Liu, P., & Chen, G. (2009). OX40-OX40 ligand interaction may activate phospholipase C signal transduction pathway in human umbilical vein endothelial cells. Chemistry & Biology Interact.
197.
Liopeta, K., Boubali, S., Virgilio, L., Thyphronitis, G., Mavrothalassitis, G., Dimitracopoulos, G., et al. (2009). cAMP regulates IL-10 production by normal human T lymphocytes at multiple levels: A potential role for MEF2. Molecular Immunology, 46, 345–354.PubMedCrossRef
198.
Forward, N. A., Furlong, S. J., Yang, Y., Lin, T. J., & Hoskin, D. W. (2009). Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. Journal of Immunology, 183, 3014–3022.CrossRef
199.
Wang, H. C., & Klein, J. R. (2001). Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: Effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation. Journal of Immunology, 167, 6717–6723.
200.
Wang, H. C., Montufar-Solis, D., Teng, B. B., & Klein, J. R. (2004). Maximum immunobioactivity of murine small intestinal intraepithelial lymphocytes resides in a subpopulation of CD43+ T cells. Journal of Immunology, 173, 6294–6302.
201.
Vu, M. D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., et al. (2007). OX40 costimulation turns off Foxp3+ Treg. Blood, 110, 2501–2510.PubMedCrossRef
202.
Colombo, M. P., & Piconese, S. (2009). Polyps wrap mast cells and Treg within tumorigenic tentacles. Cancer Research.
203.
de Vries, V. C., Wasiuk, A., Bennett, K. A., Benson, M. J., Elgueta, R., Waldschmidt, T. J., et al. (2009). Mast cell degranulation breaks peripheral tolerance. American Journal of Transplantation, 9, 2270–2280.PubMedCrossRef
204.
Piconese, S., Gri, G., Tripodo, C., Musio, S., Gorzanelli, A., Frossi, B., et al. (2009). Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood, 114, 2639–2648.PubMed
205.
Laurence, A., Tato, C. M., Davidson, T. S., Kanno, Y., Chen, Z., Yao, Z., et al. (2007). Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 26, 371–381.PubMedCrossRef
206.
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009). IL-17 and Th17 Cells. Annual Review of Immunology, 27, 485–517.PubMedCrossRef
207.
Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L., & Powrie, F. (1999). An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. The Journal of Experimental Medicine, 190, 995–1004.PubMedCrossRef
208.
Maloy, K. J., Salaun, L., Cahill, R., Dougan, G., Saunders, N. J., & Powrie, F. (2003). CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. The Journal of Experimental Medicine, 197, 111–119.PubMedCrossRef
209.
Erdman, S. E., Rao, V. P., Poutahidis, T., Ihrig, M. M., Ge, Z., Feng, Y., et al. (2003). CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Research, 63, 6042–6050.PubMed
210.
Berg, D. J., Zhang, J., Weinstock, J. V., Ismail, H. F., Earle, K. A., Alila, H., et al. (2002). Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology, 123, 1527–1542.PubMedCrossRef
211.
Brown, J. B., Lee, G., Managlia, E., Grimm, G. R., Dirisina, R., Goretsky, T., et al. (2010). Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology, 138, 595–605, 605 e591–593.
212.
Schaefer, J. S., Montufar-Solis, D., Vigneswaran, N., & Klein, J. R. (2010). ICOS promotes IL-17 synthesis in colonic intraepithelial lymphocytes in IL-10-/- mice. Journal of Leukocyte Biology, 87, 301–308.PubMedCrossRef
213.
Lochner, M., Peduto, L., Cherrier, M., Sawa, S., Langa, F., Varona, R., et al. (2008). In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+T cells. The Journal of Experimental Medicine, 205, 1381–1393.PubMedCrossRef
214.
Beriou, G., Costantino, C. M., Ashley, C. W., Yang, L., Kuchroo, V. K., Baecher-Allan, C., et al. (2009). IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood, 113, 4240–4249.PubMedCrossRef
215.
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., et al. (2009). Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity, 30, 899–911.PubMedCrossRef
216.
Zhou, X., Bailey-Bucktrout, S., Jeker, L. T., & Bluestone, J. A. (2009). Plasticity of CD4(+) FoxP3(+) T cells. Current Opinion in Immunology, 21, 281–285.PubMedCrossRef
217.
Yang, X. O., Nurieva, R., Martinez, G. J., Kang, H. S., Chung, Y., Pappu, B. P., et al. (2008). Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity, 29, 44–56.PubMedCrossRef
218.
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006). Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity, 24, 677–688.PubMedCrossRef
Metadaten
Titel
The significant role of mast cells in cancer
verfasst von
Khashayarsha Khazaie
Nichole R. Blatner
Mohammad Wasim Khan
Fotini Gounari
Elias Gounaris
Kristen Dennis
Andreas Bonertz
Fu-Nien Tsai
Matthew J. Strouch
Eric Cheon
Joseph D. Phillips
Philipp Beckhove
David J. Bentrem
Publikationsdatum
01.03.2011
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2011
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9286-z

Weitere Artikel der Ausgabe 1/2011

Cancer and Metastasis Reviews 1/2011 Zur Ausgabe

Acknowledgments

Biography — Wolf H. Fridman, M.D., Ph.D.

OriginalPaper

Modulation of tumor immunity by therapeutic monoclonal antibodies

EditorialNotes

Preface

OriginalPaper

Myeloid cell diversification and complexity: an old concept with new turns in oncology

OriginalPaper

Tumor microenvironment is multifaceted

OriginalPaper

Immunomodulating antibodies and drugs for the treatment of hematological malignancies

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen